Organon
CompanyUnited StatesROR
Organon develops 7 assets, the furthest approved (alendronate in glucocorticoid-induced osteoporosis). Mostly small molecule and supplement acting on lipid and ceramide metabolism, ESR2 and inflammation; based in the United States.
- Assets
- 7
- Furthest
- Approved
- Trials
- 135
- Signals
- 0
Pipeline
7Inhibits farnesyl pyrophosphate synthase in osteoclasts to suppress bone resorption.
ApprovedSmall moleculeLipid and ceramide metabolismFDPSglucocorticoid-induced osteoporosisosteoporosis
Estrogen receptor agonist for hormone replacement
ApprovedSmall moleculeESR2Inflammationatrophic vaginitishypogonadism
Inhibits ATP citrate lyase to reduce cholesterol biosynthesis
ApprovedSmall moleculeAMPK signallingLipid and ceramide metabolismheterozygous familial hypercholesterolemiahomozygous familial hypercholesterolemia
4 more assets
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms10
- Trials138
- Signals3
- Integrity notices3
- Similar companies6
Updated 7 Oct 2026 · 267 sources